These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 30933619)

  • 1. Cangrelor for ST-Segment-Elevation Myocardial Infarction.
    Erlinge D
    Circulation; 2019 Apr; 139(14):1671-1673. PubMed ID: 30933619
    [No Abstract]   [Full Text] [Related]  

  • 2. Cangrelor in Ticagrelor-Loaded STEMI Patients Undergoing Primary Percutaneous Coronary Intervention.
    Alexopoulos D; Pappas C; Sfantou D; Xanthopoulou I; Didagelos M; Kikas P; Ziakas A; Tziakas D; Karvounis H; Iliodromitis E
    J Am Coll Cardiol; 2018 Oct; 72(14):1750-1751. PubMed ID: 30261967
    [No Abstract]   [Full Text] [Related]  

  • 3. Cangrelor in addition to standard therapy reduces cardiac damage and inflammatory markers in patients with ST-segment elevation myocardial infarction.
    Abo-Aly M; George B; Shokri E; Chelvarajan L; El-Helw M; Smyth SS; Abdel-Latif A; Ziada K
    J Thromb Thrombolysis; 2021 Oct; 52(3):934-940. PubMed ID: 33258102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cangrelor in combination with ticagrelor provides consistent and potent P2Y12-inhibition during and after primary percutaneous coronary intervention in real-world patients with ST-segment-elevation myocardial infarction.
    Mohammad MA; Andell P; Koul S; James S; Scherstén F; Götberg M; Erlinge D
    Platelets; 2017 Jun; 28(4):414-416. PubMed ID: 27885888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discontinuation of both cangrelor and ticagrelor because of severe dyspnea during primary angioplasty.
    Di Filippo C; Caniato F; Cappelli F; Mattesini A; Meucci F; Sori A; Stolcova M; Agostini C; Bernardo P; Di Mario C
    J Cardiovasc Med (Hagerstown); 2021 Apr; 22(4):317-319. PubMed ID: 33633048
    [No Abstract]   [Full Text] [Related]  

  • 6. Cangrelor versus Ticagrelor in Patients Treated with Primary Percutaneous Coronary Intervention: Impact on Platelet Activity, Myocardial Microvascular Function and Infarct Size: A Randomized Controlled Trial.
    Ubaid S; Ford TJ; Berry C; Murray HM; Wrigley B; Khan N; Thomas MR; Armesilla AL; Townend JN; Khogali SS; Munir S; Martins J; Hothi SS; McAlindon EJ; Cotton JM
    Thromb Haemost; 2019 Jul; 119(7):1171-1181. PubMed ID: 31129911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intracoronary cangrelor administration-assisted primary percutaneous coronary intervention in a patient with essential thrombocythemia and recurrent ST-segment elevation myocardial infarction.
    Ielasi A; Loffi M; Buono A; De Blasio G; Tespili M
    J Cardiovasc Med (Hagerstown); 2020 Oct; 21(10):825-828. PubMed ID: 32740411
    [No Abstract]   [Full Text] [Related]  

  • 8. No Benefit of Ticagrelor Pretreatment Compared With Treatment During Percutaneous Coronary Intervention in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
    Koul S; Smith JG; Götberg M; Omerovic E; Alfredsson J; Venetsanos D; Persson J; Jensen J; Lagerqvist B; Redfors B; James S; Erlinge D
    Circ Cardiovasc Interv; 2018 Mar; 11(3):e005528. PubMed ID: 29870381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial.
    Abtan J; Steg PG; Stone GW; Mahaffey KW; Gibson CM; Hamm CW; Price MJ; Abnousi F; Prats J; Deliargyris EN; White HD; Harrington RA; Bhatt DL;
    JACC Cardiovasc Interv; 2016 Sep; 9(18):1905-13. PubMed ID: 27659566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Pre-Hospital Ticagrelor During the First 24 h After Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction: The ATLANTIC-H²⁴ Analysis.
    Montalescot G; van 't Hof AW; Bolognese L; Cantor WJ; Cequier A; Chettibi M; Collet JP; Goodman SG; Hammett CJ; Huber K; Janzon M; Lapostolle F; Lassen JF; Licour M; Merkely B; Salhi N; Silvain J; Storey RF; Ten Berg JM; Tsatsaris A; Zeymer U; Vicaut E; Hamm CW;
    JACC Cardiovasc Interv; 2016 Apr; 9(7):646-56. PubMed ID: 26952907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between gender and short-term outcome in patients with ST elevation myocardial infraction participating in the international, prospective, randomised Administration of Ticagrelor in the catheterisation Laboratory or in the Ambulance for New ST elevation myocardial Infarction to open the Coronary artery (ATLANTIC) trial: a prespecified analysis.
    Venetsanos D; Sederholm Lawesson S; Alfredsson J; Janzon M; Cequier A; Chettibi M; Goodman SG; Van't Hof AW; Montalescot G; Swahn E
    BMJ Open; 2017 Sep; 7(9):e015241. PubMed ID: 28939567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal P2Y12 Inhibitor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Network Meta-Analysis.
    Rafique AM; Nayyar P; Wang TY; Mehran R; Baber U; Berger PB; Tobis J; Currier J; Dave RH; Henry TD
    JACC Cardiovasc Interv; 2016 May; 9(10):1036-46. PubMed ID: 27198684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cangrelor: Pharmacology, Clinical Data, and Role in Percutaneous Coronary Intervention.
    Price MJ
    Interv Cardiol Clin; 2017 Jan; 6(1):39-47. PubMed ID: 27886821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: insights from the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]).
    White HD; Bhatt DL; Gibson CM; Hamm CW; Mahaffey KW; Price MJ; Steg PG; Stone GW; Cortese B; Wilensky M; Deliargyris EN; Liu T; Prats J; Harrington RA
    JACC Cardiovasc Interv; 2015 Mar; 8(3):424-433. PubMed ID: 25703887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of cangrelor, prasugrel, ticagrelor, and clopidogrel in patients undergoing percutaneous coronary intervention: A network meta-analysis.
    Westman PC; Lipinski MJ; Torguson R; Waksman R
    Cardiovasc Revasc Med; 2017 Mar; 18(2):79-85. PubMed ID: 28089137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cangrelor in Percutaneous Coronary Intervention: Current Status and Perspectives.
    Alexopoulos D; Pappas C; Sfantou D; Lekakis J
    J Cardiovasc Pharmacol Ther; 2018 Jan; 23(1):13-22. PubMed ID: 29228817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is Treatment of ST-Segment-Elevation Myocardial Infarction Patients With Ticagrelor or Other P2Y
    Huber K
    Circ Cardiovasc Interv; 2018 Mar; 11(3):e006555. PubMed ID: 29870388
    [No Abstract]   [Full Text] [Related]  

  • 18. Impact of oral P2Y12 inhibitors on residual thrombus burden and reperfusion indexes in patients with ST-segment elevation myocardial infarction.
    Di Vito L; Versaci F; Limbruno U; Pawlowski T; Gatto L; Romagnoli E; Cattabiani MA; Micari A; Trivisonno A; Marco V; Prati F
    J Cardiovasc Med (Hagerstown); 2016 Sep; 17(9):701-6. PubMed ID: 27467458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of Microvascular Injury in Revascularized Patients With ST-Segment-Elevation Myocardial Infarction Treated With Ticagrelor Versus Prasugrel.
    van Leeuwen MAH; van der Hoeven NW; Janssens GN; Everaars H; Nap A; Lemkes JS; de Waard GA; van de Ven PM; van Rossum AC; Ten Cate TJF; Piek JJ; von Birgelen C; Escaned J; Valgimigli M; Diletti R; Riksen NP; van Mieghem NM; Nijveldt R; van Royen N
    Circulation; 2019 Jan; 139(5):636-646. PubMed ID: 30586720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pretreatment with P2Y12 inhibitors and outcome in patients with ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention.
    Gach O; Nyssen A; Pirlet C; Magne J; Oury C; Lancellotti P
    J Cardiovasc Med (Hagerstown); 2018 May; 19(5):234-239. PubMed ID: 29528868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.